Gene Expression Regulation, Neoplastic

"Gene Expression Regulation, Neoplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.

Descriptor ID	D015972
MeSH Number(s)	G05.308.370
Concept/Terms	Gene Expression Regulation, Neoplastic Gene Expression Regulation, Neoplastic Regulation of Gene Expression, Neoplastic Regulation, Gene Expression, Neoplastic Neoplastic Gene Expression Regulation

Below are MeSH descriptors whose meaning is more general than "Gene Expression Regulation, Neoplastic".

Biological Sciences [G]
Genetic Phenomena [G05]
Gene Expression Regulation [G05.308]
Gene Expression Regulation, Neoplastic [G05.308.370]

Below are MeSH descriptors whose meaning is more specific than "Gene Expression Regulation, Neoplastic".

Gene Expression Regulation, Neoplastic
Gene Expression Regulation, Leukemic

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Gene Expression Regulation, Neoplastic" by people in this website by year, and whether "Gene Expression Regulation, Neoplastic" was a major or minor topic of these publications.

Bar chart showing 950 publications over 30 distinct years, with a maximum of 61 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	5	9	14
1997	6	10	16
1998	3	9	12
1999	4	6	10
2000	8	6	14
2001	4	8	12
2002	6	16	22
2003	9	20	29
2004	10	21	31
2005	15	20	35
2006	14	18	32
2007	21	18	39
2008	20	24	44
2009	18	21	39
2010	19	33	52
2011	23	35	58
2012	8	39	47
2013	24	31	55
2014	14	31	45
2015	22	39	61
2016	21	36	57
2017	11	29	40
2018	11	30	41
2019	10	31	41
2020	10	28	38
2021	13	23	36
2022	0	6	6
2023	0	4	4
2024	2	16	18
2025	0	2	2

Below are the most recent publications written about "Gene Expression Regulation, Neoplastic" by people in Profiles.

Islam R, Roche ME, Lin Z, Whitaker-Menezes D, Diaz-Barros V, Serrano E, Martinez Cantarin MP, Philp NJ, Basu Mallick A, Martinez-Outschoorn U. TOMM20 as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis. Mol Oncol. 2025 Aug; 19(8):2431-2455.

View in: PubMed
Hartmann HA, Loberg MA, Xu GJ, Schwarzkopf AC, Chen SC, Phifer CJ, Caroland K, Chen HC, Diaz D, Tigue ML, Hesterberg AB, Gallant JN, Shaddy SM, Sheng Q, Netterville JL, Rohde SL, Sol?rzano CC, Bischoff LA, Baregamian N, Hurley PJ, Murphy BA, Choe JH, Huang EC, Ye F, Lee E, Weiss VL. Tenascin-C Potentiates Wnt Signaling in Thyroid Cancer. Endocrinology. 2025 Feb 05; 166(3).

View in: PubMed
Mittal P, Battaglin F, Baca Y, Xiu J, Farrell A, Soni S, Lo JH, Torres-Gonzalez L, Algaze S, Jayachandran P, Ashouri K, Wong A, Zhang W, Yu J, Zhang L, Weinberg BA, Lou E, Shields AF, Goldberg RM, Marshall JL, Goel S, Singh IK, Lenz HJ. Comprehensive characterization of MCL-1 in patients with colorectal cancer: Expression, molecular profiles, and outcomes. Int J Cancer. 2025 04 15; 156(8):1583-1593.

View in: PubMed
Nguyen AL, Facey COB, Boman BM. The Significance of Aldehyde Dehydrogenase 1 in Cancers. Int J Mol Sci. 2024 Dec 30; 26(1).

View in: PubMed
Toracchio L, Carrabotta M, Mancarella C, Morrione A, Scotlandi K. EphA2 in Cancer: Molecular Complexity and Therapeutic Opportunities. Int J Mol Sci. 2024 Nov 13; 25(22).

View in: PubMed
Arai H, Gandhi N, Battaglin F, Wang J, Algaze S, Jayachandran P, Soni S, Zhang W, Yang Y, Millstein J, Lo JH, Sohal D, Goldberg R, Hall MJ, Scott AJ, Hwang JJ, Lou E, Weinberg BA, Marshall J, Goel S, Xiu J, Korn WM, Lenz HJ. Role of CD47 gene expression in colorectal cancer: a comprehensive molecular profiling study. J Immunother Cancer. 2024 11 05; 12(11).

View in: PubMed
Dup?r?-Richer D, Riva A, Barwick BG, Maji S, Casellas Rom?n H, Li J, De U, Sobh A, Quickstad G, Piper C, Kulis M, Ezponda T, Mart?n-Subero JI, Tonon G, Zhang W, Mitsiades CS, Boise LH, Bennett RL, Licht JD. KDM6A regulates immune response genes in multiple myeloma. Blood. 2024 10 03; 144(14):1508-1520.

View in: PubMed
Sardar S, McNair CM, Ravindranath L, Chand SN, Yuan W, Bogdan D, Welti J, Sharp A, Ryan NK, Knudsen LA, Schiewer MJ, DeArment EG, Janas T, Su XA, Butler LM, de Bono JS, Frese K, Brooks N, Pegg N, Knudsen KE, Shafi AA. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer. Oncogene. 2024 10; 43(43):3197-3213.

View in: PubMed
Wasserman JS, Fowle H, Hashmi R, Atar D, Patel KR, Yarmahmoodi A, Macfarlane AW, Tan Y, Cukierman E, Gligorijevic B, Karami A, Whelan KA, Campbell KS, Gra?a X. Derivation of human primary prostate epithelial cell lines by differentially targeting the CDKN2A locus along with expression of hTERT. Sci Rep. 2024 09 02; 14(1):20409.

View in: PubMed
Chehade H, Gogoi R, Adzibolosu NK, Galoforo S, Fehmi RA, Kheil M, Fox A, Kim S, Rattan R, Hou Z, Morris RT, Matherly LH, Mor G, Alvero AB. BRCA Status Dictates Wnt Responsiveness in Epithelial Ovarian Cancer. Cancer Res Commun. 2024 08 01; 4(8):2075-2088.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement